# Hoffman Predicts AI-Driven Drug Discovery Bonanza > Source: > Published: 2026-05-28 15:36:28.193433+00:00 # Hoffman Predicts AI-Driven Drug Discovery Bonanza According to Business Insider, Reid Hoffman, cofounder of LinkedIn and Manas AI, said on "The Possible Podcast" that "Now it's the time for medicine," and argued that AI-driven drug discovery represents a larger total addressable market than the current chatbot revenue opportunities. Business Insider reports Hoffman said the AI chatbot boom already has leading players such as OpenAI and Anthropic, and that companies using AI can accelerate early-stage research to shorten the lengthy drug development timeline, which Business Insider notes can take over **10 years**. Hoffman is quoted describing Manas AI's work as "creating a drug discovery factory for monopolies," referencing the typical **20-year** patent term, according to Business Insider. ### What happened According to Business Insider, Reid Hoffman, cofounder of **LinkedIn** and **Manas AI**, said on "The Possible Podcast" that "Now it's the time for medicine." Business Insider reports Hoffman argued that AI-driven drug discovery offers a larger total addressable market than the current AI chatbot revenue pools led by companies such as **OpenAI** and **Anthropic**. Business Insider also reports Hoffman said the drug development timeline can take over **10 years**, and quotes him describing Manas AI as "creating a drug discovery factory for monopolies," referencing the **20-year** patent term. ### Editorial analysis - technical context Industry-pattern observations: applying AI to drug discovery typically combines large biological datasets, generative molecular design, and iterative wet-lab validation. Companies in this space rely on richer labelled biochemical and phenotypic data than many consumer AI applications, and they must integrate predictive models with experimental throughput and preclinical pipelines. For practitioners, that means model performance alone is necessary but not sufficient; data provenance, assay reproducibility, and tight experiment-model cycles matter more than in purely digital products. ### Context and significance Industry context: Commentary from a prominent investor-founder like Reid Hoffman highlights shifting investor attention toward biopharma applications of AI. Historical patterns show that when capital flows into biotech-AI, it accelerates partnerships between model developers and contract research organisations, expands compute and data acquisition budgets, and increases emphasis on validation to meet regulatory requirements. That pattern raises practical challenges for teams building models that need to generalise across assay types and translate to in vivo results. ### What to watch Observers should track three indicators: reported clinical candidates originating from AI-first discovery platforms, published retrospective validation studies that link in silico predictions to experimental outcomes, and partnership announcements between AI startups and established pharma or CROs. Also monitor regulatory guidance updates that affect evidence expectations for AI-assisted candidate selection. ### Reported-source note All quotes and attributions in this briefing are drawn from Business Insider's May 28, 2026 coverage of Reid Hoffman's comments on "The Possible Podcast." ## Scoring Rationale Comments from a high-profile investor-founder shift attention and potentially capital toward AI in drug discovery, a notable development for practitioners and funders. The story is influential but not a technical breakthrough or regulatory event. Practice interview problems based on real data 1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with. [Try 250 free problems](/problems)